Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q2 2022 · 10-Q
Revenue$453.33M$453.33M+15.0% vs Q2 2021 Net Income$39.11M$39.11M−16.7% vs Q2 2021 EPS Diluted$3.42$3.42−13.6% vs Q2 2021 Gross Profit$321,682,000+9.5% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Operating Cash Flowderived$43,762,000+109.6% Free Cash Flowderived$40,922,000+208.1% Margins · derivedGross margin71.0%−3.5 pt vs Q2 2021
Operating margin10.8%−4.8 pt vs Q2 2021
Net margin8.6%−3.3 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 3, 2022 · 34 d after period end